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Peripheral arterial disease (PAD) is associated with a high morbidity and mortality, largely from coronary and cerebro-
vascular disease, which often overshadows the PAD itself. Best Medical Therapy (BMT), comprising smoking cessation,
antiplatelet agent use, cholesterol reduction, exercise therapy, and the diagnosis and treatment of hypertension and diabetes
mellitus; is evidenced based and can result in significant reductions in cardiovascular risk, as well as some improvement in
PAD. Previous data have largely been restricted to patients with coronary artery disease, and their relevance to PAD has
been extrapolated. However, data are now starting to become available, such as the Heart Protection Study, with data
specific to PAD patients. This article reviews the data regarding the use of BMT in patients with PAD, and based on this,
makes recommendations for the use of BMT in this group of patients.
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Peripheral arterial disease (PAD) is common, with
over 20% of the population having asymptomatic dis-
ease, and up to 5% having lower limb symptoms; most
commonly, intermittent claudication.1 Although inter-
mittent claudication is relatively benign in terms of
limb-loss (1±2% per year), it is associated with a vas-
cular mortality (5±10% per year) 2±4 times greater
than that of an age and sex matched non-claudicant
population; a risk that is, in fact, greater than that
experienced by patients with angina.2 There are
several reasons for this.
 PAD is a marker for severe, multi-system athero-
sclerosis affecting the cerebral, visceral and coron-
ary arteries.3
 In the presence of exercise-limiting intermittent
claudication, even severe ischaemic heart disease
may be asymptomatic and thus go unrecognised
and untreated.
 There is some evidence that repeated ischaemia-
reperfusion of leg muscles may lead to a systemicPlease address all correspondence to: A. W. Bradbury, Professor of
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sclerosis and promotes thrombotic events.4
 But most importantly, research into the benefits of
risk factor modification and best medical treatment
(BMT) in PAD patients has lagged far behind that
directed towards symptomatic ischaemic heart dis-
ease. This in turn has resulted in:
 a less compelling evidence base for treatment.
 a lack of awareness of the vascular risk faced by
these patients.
 a belief that the costs of instituting BMT in
patients with PAD could not be justified.
For these reasons, rather than viewing the PAD
patient in a holistic way as a vascular `` time-bomb'',
those treating PAD have tended to focus on the arter-
ial lesion and its surgical or endovascular (angio-
plasty, stenting) treatment. Unfortunately, with the
notable exception of carotid intervention for high-
grade symptomatic disease,5±7 there is little or no
level 1 evidence to support intervention for PAD that
is not immediately life or limb-threatening. What little
data are available suggest that invasive intervention
for claudication can lead to an early (1 year) improve-
ment in symptoms, but there is no evidence this is
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Fig. 1. Benefit of 40 mg simvastatin from The Heart Protection Study.
Number of vascular events by prior disease. Data taken from
www.hpsinfo.org. MI: myocardial infarction; CHD: coronary heart
disease; CVD: cerebrovascular disease.
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and do not impact upon the patients' high underling
vascular risk.10,11 By contrast, there is increasing and
compelling evidence that BMT comprising anti-
smoking strategies, antiplatelet agents, lipid lowering
and exercise programmes dramatically reduce the
vascular risk and significant increase functional sta-
tus.12,13 BMT is also relatively inexpensive and virtu-
ally free from risk. With the release of data from the
Heart Protection Study, which included over 6000
patients with PAD and confirmed the benefits of
lipid lowering, it is timely to review what BMT should
comprise and how it can be instituted universally in
patients with PAD.14
Anti-smoking strategies
There is overwhelming evidence that smoking is the
single most important risk factor for the development
and progression of PAD and that it significantly
increases the risk, and reduces the success, of periph-
eral arterial intervention.12,15±20 Despite the clear
benefits of smoking cessation in PAD patients, only
a minority (11±48%) of patients manage to quit.21
Simple oral advice is ineffective,22 but more intensive
counselling has been shown to be effective in unselect-
ed smokers, although not in PAD patients.23±25 Nico-
tine replacement therapy, whether delivered by patch,
gum, intranasal spray, inhaler or sublingual tablet, is
safe, and leads to significant improvements in smok-
ing cessation (odds ratio 1.72, 95% confidence interval
1.60±1.84); at least in the short term.26,27 Bupropion is
at least as effective as nicotine replacement therapy,
but appears to confer no additional benefit in combin-
ation with nicotine replacement therapy.28 The
Cochrane group on tobacco addiction has found alter-
native therapies such as acupuncture, hypnotherapy,
and `` aversive smoking'', to be ineffective.29±31
Hypercholesterolaemia
Hypercholesterolaemia is clearly an independent risk
factor for the development and progression of
PAD.2,15,16,32 Cholesterol lowering has been shown to
slow the progression of peripheral atherosclerosis in a
number of large, including randomised, anatomical
and pathological studies,33,34 although none have
shown benefit with respect to PAD symptoms. The
recently concluded Heart Protection Study has, for
the first time, demonstrated a benefit of statins in
PAD patients by reducing coronary events by 20%.
Furthermore, this was achieved irrespective of start-
ing total cholesterol35 (Fig. 1). Detailed, peer-reviewedresults are awaited, but this could have significant
implications for cholesterol lowering in patients with
PAD. Whether there is benefit from raising high
density lipoproteins, and reducing triglycerides levels
is less clear.36
In summary, all patients with PAD should have
their cholesterol reduced with aggressive statin ther-
apy, regardless of starting total cholesterol. In the
longer term it seems possible that statin therapy will
be indicated for any patient with objective evidence of
asymptomatic PAD; for example, as demonstrated by
a reduced ankle : brachial pressure index. As patents
expire, and generic drugs become available, the finan-
cial consequences of these massive changes in pre-
scribing practice will ease and, of course, the
prevention of large numbers of vascular events will
also help to offset the costs.
Antiplatelet Therapy
Early studies suggested antiplatelet agents could pro-
duce angiographic improvement,37 increase walking
distance,38,39 and reduce the requirement for vascular
intervention.40 There is overwhelming evidence from
the Antiplatelet Trialists' Collaboration that the pre-
scription of an anti-platelet agent, usually aspirin,
reduces vascular death in patients with symptomatic
atherosclerotic disease by about 25%.41 Most of the
studies were in patients with ischaemic heart disease
and, when taken in isolation, data from the few stu-
dies looking specifically at patients with PAD wereEur J Vasc Endovasc Surg Vol 24, July 2002
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trials has shown that, when compared with placebo,
APA treatment reduced the risk of death by about a
quarter in patients with PAD.42
In summary, all patients with PAD should be on an
antiplatelet agents because it reduces vascular event
and death, improves the patency rates of surgery and
endovascular interventions and may improve walking
distance. For reasons of cost, non-enteric aspirin
(75 mg) is a reasonable first-line choice as there is no
clear evidence that a higher dose is more effective (but
will cause more adverse events) or that enteric coating
is associated with less gastric upset (and is more
expensive). Patients who cannot take aspirin should
be considered for clopidogrel.
Exercise
There is little doubt that exercise leads to a significant
improvement in exercise tolerance (most studies show
at least a doubling in walking distance) in patients
with PAD.43±45 It is also likely, though not specifically
proved, that exercise will reduce vascular risk. How-
ever, clinicians and academics alike have largely
neglected this simple, inexpensive and effective ther-
apy; and as such, many important questions remain
unanswered.
How does exercise work? Whilst early animal stu-
dies suggested that exercise may improve blood flow
by the development of collaterals, studies in humans
using venous occlusion plethysmography, Xenon-133
clearance and duplex ultrasonography have not con-
firmed this.46 Despite this, exercise training can lead to
increased clearance of Xenon-133 injected into calf
muscles, possibly indicating that blood is being
diverted towards more active muscles. Exercise train-
ing in claudicants leads to increases in oxidative
enzymes, and enhanced utilization of fatty acids in
the calf muscles, maximising the use of oxygen deliv-
ered to the tissues. Improvements in walking distance
may also be due to improvements in walking
biomechanics47 and blood rheology.48
What is the best form of exercise? It has generally
been thought to be walking but recent data have sug-
gested that arm exercise, may be at least as beneficial,
which further questions the mechanism by which
exercise achieves its benefit.49
Does exercise have beneficial effects on risk factor
profile? A small non-randomised controlled trail
showed that exercise training for claudicants, can
lead to modest reductions in blood pressure, choles-
terol and glucose levels.51 Whether this translates to a
significant improvement in cardiovascular risk, hasEur J Vasc Endovasc Surg Vol 24, July 2002not been specifically determined in claudicants, but
data from ischaemic heart disease patients suggests
that it may.50
Should exercise be supervised and, if so, how and
for how long? Supervised exercise programmes
would seem intuitively to be better, but there is little
evidence to support this. Gardner and Poehlman
reviewed 21 studies of exercise therapy in PAD, and
found that supervised exercise programmes were no
better than unsupervised. A small randomised study
of 54 patients, comparing a 12 week supervised exer-
cise programme and unsupervised exercise, did sug-
gest that the supervised programme was superior
(improvement in maximum walking distance 207 vs
70% at 6 months). What is unclear, is the durability of
any benefit. It might be speculated that any advantage
of supervised exercise will diminish with time,
although there is no evidence to support this.
Until these issues are addressed one must approach
this aspect of care in a pragmatic way based upon
local resources. PAD patients should certainly be
repeatedly and specifically informed that exercise is
beneficial and that it is not (as far as we know) harm-
ful to try to `` walk through'' their claudication pain.
Written advice may be a useful adjunct although this
suggestion is not evidence-based. Although super-
vised programmes may be superior, at least in the
U.K., such programmes are not widely available. The
ongoing, U.K.-based, Heath Technology Assessment
funded Exercise versus angioplasty in claudication
trial (EXACT) will provide more information about
the relative benefits of exercise and angioplasty
when it reports (for more information please contact
the senior author).
Diabetes
Diabetics have a 3±5 fold increased risk of PAD, and
are at increased risk of progression from intermittent
claudication to critical limb ischaemia.52,53 The U.K.
Prospective Diabetes Study has shown that intensive
control decreased the risk of microvascular but not
macrovascular vascular complications of the dis-
ease.54 However, it is extremely important that the
diagnosis of diabetes be specifically confirmed or
excluded in patients with PAD because it will affect
other areas of their treatment, such as blood pressure
and lipid control.55,56
Blood Pressure Control
Hypertension, particularly, systolic hypertension,
is associated with a three-fold increase in the risk
Best Medical Therapy for Peripheral Arterial Disease 9of developing PAD.57±59 No study has specifically
investigated PAD patients but it is quite clear that in
general the treatment of hypertension significantly
reduces coronary events and stroke.60 Traditionally,
blood pressure has been treated to a level of 160/90,
but more recent data suggest that tighter control (130±
140/85 mmHg) might confer additional benefits.61 It is
frequently taught that  blockers are contra-indicated
PAD, but there is no evidence to support this.62
Other Risk Factors
Hyperhomocysteinaemia is becoming increasingly
recognised as an important risk factor for develop-
ment of atherosclerosis, and cross-sectional studies
have linked it specifically to PAD.63 However, the
effect of reducing homocysteine levels has yet to
defined, but should be answered by several ongoing
trials. Observational studies have suggested that low
levels of anti-oxidant vitamins are associated with
PAD, although no studies, including the Heart Protec-
tion Study, have yet shown any benefit from vitamin
supplementation.14,64,65
The relationship between alcohol and PAD appears
to be J shaped, with minimal risk occurring at around
2 units of alcohol per day.66 Excess alcohol consump-
tion is clearly associated with an increased vascular
risk. Oestrogen has been proposed as being cardio
protective, on the basis of reduced cardiovascular
morbidity and mortality in women taking hormone
replacement therapy, but a recent randomised con-
trolled trials showed no difference in cardiovascular
events between groups randomised to oestrogen/
progestogen, and placebo.67 In summary, these factors
may represent important risk factors in PAD, but at
present there is insufficient evidence to justify target-
ing them for treatment.
Prevalence of BMT use in PAD
Despite the overwhelming evidence for BMT in
patients with PAD, clinical experience and theTable 1. The use of cholesterol-lowering and anti-thrombotic therap
Study n Patient population
Clark et al. (1999)68 299 Admitted for angiography
Anand et al. (1999)70 195 Admitted for peripheral
arterial surgery
Bismuth et al. (2000)69 147 Critical limb ischaemia
McDermott et al. (1997)71 202 ABPI50.9 or abnormal
Doppler waveformliterature indicated that it has been poorly applied in
the past (Table 1). The proportion of patients taking
any kind of anti-thrombotic therapy or warfarin
ranges from 39% to 66%, and prevalence of cholesterol
lowering therapy ranges from 5% to 46%. Patients
who also have symptomatic ischaemic heart disease
seem more likely to be treated but, in general there
seems little or no relationship between the prevalence
of treatment, the severity of the underlying disease
and thus the potential benefits of BMT.68±71 In other
words, treatment is haphazard rather that the result
of evidence.
The current situation is unacceptable, and clearly
strategies need to be put in place to ensure that PAD
patients do not miss out on evidence-based life saving
treatment. The initial step needs to be the education
of health professionals working with PAD patients
about the increased cardiovascular risk of these
patients, and the benefits of BMT. Articles such as
this should raise the profile of these important issues.
One strategy to increase the institution of BMT is
the use of record cards (Fig. 2). These chart the level
of individual risk factors over time, and allow easy
recognition for healthcare professionals of untreated,
or inadequately treated risk factors. These charts
could be held in the case notes, or by the patient.
Another possibility for increasing BMT use is to have
dedicated staff in out-patient clinics. This is an ideal
role for clinical nurse specialists, who are increasing in
number. Whatever technique is employed, it is
important to co-ordinate the patient's care with
primary care.
Summary
There is overwhelming evidence for the efficacy of
BMT in PAD, in terms of cardiovascular risk reduc-
tion, and improvement in PAD symptoms. Recom-
mendations for the use of BMT, based on the best
evidence available to date are presented in Table 2.
Despite the evidence of benefit, BMT is grosslyy (antiplatelet agent of warfarin) in patients with PAD.
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66 (45) 8 (5) 58 (39)
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Fig. 2. Best Medical Therapy chart.
Table 2. Recommendations for best medical therapy (BMT) in
patients with PAD.
Component of BMT Recommendation




Cholesterol reduction Cholesterol checked yearly
Statin therapy if total cholesterol 45.0
Additional treatment will be
required if HDL low, or triglycerides
high (Referral to lipid clinic)
Antiplatelet agent Aspirin
Clopidogrel if aspirin intolerant
Diabetes mellitus Screen for diabetes mellitus
Blood pressure Reduce blood pressure to 5140/80 mmHg
Exercise Patients with lower limb disease should
be prescribed a supervised exercise
programme
10 P. Burns et al.underused in PAD patients. If BMT use increases, this
will lead to a decrease in cardiovascular morbidity
and mortality, a reduction in the requirement for
peripheral vascular intervention, and an improve-
ment in outcome for those interventions that areEur J Vasc Endovasc Surg Vol 24, July 2002required. It is imperative that those involved in the
care of patients with PAD are aware of the benefit of
BMT, and develop strategies to help improve its
implementation.
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